China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced receiving a prestigious patent award from the China National Intellectual Property Administration (CNIPA) for its in-house developed human antibody mice RenMab platform. This recognition underscores the company’s commitment to innovation in the field of antibody development.
RenMab Technology Platform Overview
The RenMab technology platform is a groundbreaking mouse model capable of completely replacing human antibody heavy chain and light chain variable region genes. This advanced platform is designed to generate human monoclonal antibodies with excellent diversity, strong specificity, high affinity, and superior physical and chemical properties. The platform’s capabilities significantly enhance the efficiency of human antibody drug development and expedite the overall development process.
Global Patent Protection for RenMab
Recognizing the global potential of the RenMab platform, Biocytogen has filed for patent protection in several key jurisdictions, including the US, Europe, Japan, Singapore, Russia, Israel, and Australia. This strategic move ensures that the company’s innovative technology is protected and positions Biocytogen as a leader in the global biotechnology sector.-Fineline Info & Tech
